TY - JOUR
T1 - Significance of perivesical lymph nodes in radical cystectomy for bladder cancer
AU - Hu, Brian
AU - Satkunasivam, Raj
AU - Schuckman, Anne
AU - Sherrod, Andy
AU - Cai, Jie
AU - Miranda, Gus
AU - Daneshmand, Siamak
N1 - Publisher Copyright:
© 2014 Elsevier Inc.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014
Y1 - 2014
N2 - Objective: The location of positive lymph nodes (LNs) is important for bladder cancer staging. Little is known regarding the impact of perivesical (PV) lymph node (PVLN) involvement on survival. This study characterized PVLN identified after radical cystectomy (RC) and analyzed their impact on recurrence and survival. Materials and methods: We reviewed our institutional review board-approved database including all patients who underwent RC with pelvic lymphadenectomy for curative intent for urothelial carcinoma. Clinical and pathologic data were obtained. Patients were analyzed in groups according to the location of positive LNs: PV+/other LN (ON)+, PV+/ON-, and PV-/ON+. Kaplan-Meier curves were used to estimate recurrence-free survival (RFS) and overall survival (OS). Multivariable Cox regression (including pathologic T category, number of positive LNs, highest level of positive LNs, chemotherapy, and margin status) was performed to evaluate associations between PVLN status and survival. Results: In total, 2,017 patients met inclusion criteria and 465 (23%) were LN+. PVLNs were identified in 936 patients (47%), positive in 197 patients (10%), and represented isolated LN+disease in 101 patients (5%). On univariate analysis, RFS and OS were significantly worse in the PV+/ON+group compared with the PV+/ON- and PV-/ON+ groups. There were no significant differences in RFS or OS between the PV+/ON- and PV-/ON+ groups. On multivariable analysis, PV+/ON+disease was independently associated with worse RFS and OS when compared with PV-/ON+ disease. Conclusions: PVLNs were identified in a significant number of patients after RC. Positive PVLN, when in combination with other positive LNs, portends worse survival even when correcting for the number of positive nodes.
AB - Objective: The location of positive lymph nodes (LNs) is important for bladder cancer staging. Little is known regarding the impact of perivesical (PV) lymph node (PVLN) involvement on survival. This study characterized PVLN identified after radical cystectomy (RC) and analyzed their impact on recurrence and survival. Materials and methods: We reviewed our institutional review board-approved database including all patients who underwent RC with pelvic lymphadenectomy for curative intent for urothelial carcinoma. Clinical and pathologic data were obtained. Patients were analyzed in groups according to the location of positive LNs: PV+/other LN (ON)+, PV+/ON-, and PV-/ON+. Kaplan-Meier curves were used to estimate recurrence-free survival (RFS) and overall survival (OS). Multivariable Cox regression (including pathologic T category, number of positive LNs, highest level of positive LNs, chemotherapy, and margin status) was performed to evaluate associations between PVLN status and survival. Results: In total, 2,017 patients met inclusion criteria and 465 (23%) were LN+. PVLNs were identified in 936 patients (47%), positive in 197 patients (10%), and represented isolated LN+disease in 101 patients (5%). On univariate analysis, RFS and OS were significantly worse in the PV+/ON+group compared with the PV+/ON- and PV-/ON+ groups. There were no significant differences in RFS or OS between the PV+/ON- and PV-/ON+ groups. On multivariable analysis, PV+/ON+disease was independently associated with worse RFS and OS when compared with PV-/ON+ disease. Conclusions: PVLNs were identified in a significant number of patients after RC. Positive PVLN, when in combination with other positive LNs, portends worse survival even when correcting for the number of positive nodes.
KW - Bladder cancer
KW - Lymph node
KW - Perivesical
KW - Radical cystectomy
KW - Urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84925968878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925968878&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2014.08.004
DO - 10.1016/j.urolonc.2014.08.004
M3 - Article
C2 - 25238701
AN - SCOPUS:84925968878
SN - 1078-1439
VL - 32
SP - 1158
EP - 1165
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 8
ER -